# S100A8 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- S100A8, a calcium-binding protein, forms the calprotectin heterodimer with S100A9, acting as a major damage-associated molecular pattern (DAMP) molecule that signals through Toll-like Receptor 4 (TLR4) and Receptor for Advanced Glycation End-products (RAGE) to drive innate immune responses and inflammation.
- Elevated fecal calprotectin (S100A8/S100A9) levels, typically >50 µg/g, are a sensitive diagnostic biomarker for inflammatory bowel disease (IBD), distinguishing it from irritable bowel syndrome (IBS) with high accuracy.
- Calprotectin exhibits direct antimicrobial activity by sequestering essential metal ions like zinc and manganese, a mechanism exploited by pathogens such as *Staphylococcus aureus* through proteins like SSL7 to evade host defenses.
- Therapeutic strategies targeting S100A8 and its heterodimer include monoclonal antibodies and small-molecule inhibitors like paquinimod and tasquinimod, which aim to block receptor interactions or disrupt heterodimer formation, showing promise in treating inflammatory diseases and certain cancers.
- S100A8's nuclear translocation, facilitated by phosphorylation at Ser113, allows it to interact with tumor suppressor p53 and modulate the unfolded protein response via GADD34, contributing to cancer progression and cellular stress responses.

---

## Executive Summary & Key Metadata

S100A8 (also known as calgranulin A, MRP8, or migration inhibitory factor-related protein 8) is a small (10.8 kDa) calcium-binding protein belonging to the S100 family of EF-hand proteins. It is constitutively expressed in neutrophils and monocytes, where it forms heterodimeric complexes with S100A9 (calgranulin B, MRP14). The S100A8/S100A9 heterodimer, commonly referred to as calprotectin, constitutes approximately 40–50% of the cytosolic protein content in neutrophils and functions as a major damage-associated molecular pattern (DAMP) molecule. Beyond its canonical role in innate immunity, S100A8 has emerged as a critical regulator of inflammation, cancer progression, and metabolic homeostasis. This reference manual provides a comprehensive analysis of the S100A8 gene, from its genomic architecture to its clinical and therapeutic relevance.

| **Attribute** | **Detail** |
|---|---|
| HGNC Symbol | S100A8 |
| UniProt Accession | P05109 |
| Representative PDB ID | 1MR8 (heterodimer with S100A9), 4GGF (human S100A8/S100A9 complex) |
| Chromosomal Locus | 1q21.3 (epidermal differentiation complex) |
| Gene Size | ~4.5 kb (genomic) |
| mRNA Length | 543 bp (coding sequence: 279 bp) |
| Primary Molecular Function | Calcium-binding, DAMP signaling, chemotaxis, regulation of inflammation |
| Protein-Protein Interactions | S100A9 (obligate heterodimer), TLR4, RAGE, p53, GADD34 |
| Disease Associations | Rheumatoid arthritis, inflammatory bowel disease, cystic fibrosis, multiple cancers, sepsis, atherosclerosis |
| Expression Pattern | Myeloid cells (neutrophils, monocytes), keratinocytes, epithelial cells (induced) |
| Post-Translational Modifications | Phosphorylation (Ser113), oxidation (Cys42), S-nitrosylation |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Genomic Context

The S100A8 gene is located on the long arm of chromosome 1 at band q21.3 (chr1:153,390,446–153,392,116 on GRCh38/hg38). This region is part of the epidermal differentiation complex (EDC), a ~2 Mb genomic cluster containing more than 50 genes involved in epidermal differentiation, innate immunity, and inflammation. The EDC is characterized by high gene density and the presence of multiple S100 family members arranged in tandem: S100A1, S100A2, S100A3, S100A4, S100A5, S100A6, S100A7, S100A8, S100A9, S100A10, S100A11, and S100A12. The genomic organization of S100A8 is notable for its proximity to S100A9; the two genes are separated by only ~15 kb and share a bidirectional promoter region, facilitating coordinated transcriptional regulation.

### 1.2 Gene Structure and Promoter Architecture

The S100A8 gene spans approximately 4.5 kb and consists of three exons and two introns. Exon 1 (non-coding) contains the 5' untranslated region (UTR) and the transcriptional start site (TSS). Exon 2 encodes the N-terminal EF-hand domain (helix I, loop I, helix II) and the hinge region. Exon 3 encodes the C-terminal EF-hand domain (helix III, loop III, helix IV) and the 3' UTR. The intronic sequences are relatively short (intron 1: ~1.2 kb; intron 2: ~2.1 kb), consistent with the compact architecture of S100 genes.

The promoter region of S100A8 lacks a canonical TATA box but contains multiple GC-rich elements and binding sites for transcription factors critical for myeloid-specific expression. Key regulatory elements include:

- **C/EBPα (CCAAT/enhancer-binding protein alpha)**: Binding sites at positions −120 to −110 and −60 to −50 relative to the TSS. C/EBPα is essential for basal expression in myeloid progenitors.
- **PU.1 (Spi-1 proto-oncogene)**: A purine-rich sequence at −80 to −70 that cooperates with C/EBPα to drive myeloid-specific transcription.
- **NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells)**: Two consensus binding sites (GGGRNNYYCC) at −200 and −150 that mediate lipopolysaccharide (LPS)-induced upregulation.
- **STAT3 (signal transducer and activator of transcription 3)**: A binding site at −170 that responds to interleukin-6 (IL-6) family cytokines.
- **Glucocorticoid response elements (GREs)**: Negative regulatory elements that mediate dexamethasone-induced suppression.

### 1.3 Enhancer Elements and Chromatin Architecture

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) studies have identified several enhancer elements within the S100A8 locus. A myeloid-specific enhancer located ~5 kb upstream of the TSS (chr1:153,385,000–153,386,500) is marked by H3K27ac (histone H3 lysine 27 acetylation) and H3K4me1 (histone H3 lysine 4 monomethylation) in CD14+ monocytes but not in lymphocytes. This enhancer contains binding sites for RUNX1 (runt-related transcription factor 1) and C/EBPβ, and its deletion in reporter assays reduces LPS-induced expression by ~70%. Additionally, a super-enhancer spanning the S100A8–S100A9 intergenic region has been described in neutrophils, coordinating high-level expression during granulopoiesis.

### 1.4 Alternative Splicing and Isoforms

The S100A8 gene undergoes limited alternative splicing. The predominant transcript (ENST00000368768.8) encodes the canonical 93-amino acid protein. A minor splice variant lacking exon 2 (ENST00000455392.5) has been detected in human keratinocytes; this isoform produces a truncated protein of 48 amino acids that lacks the N-terminal EF-hand and is predicted to be non-functional due to loss of calcium-binding capacity. However, this variant is expressed at very low levels (<1% of total S100A8 mRNA) and its physiological relevance remains uncertain. No evidence supports the existence of secreted isoforms or proteolytically processed variants with distinct functions, although extracellular S100A8 can undergo post-translational modifications (see Section 3).

### 1.5 Pseudogenes and Regulatory RNAs

One processed pseudogene (S100A8P1) has been identified on chromosome 11q13, but it lacks promoter elements and is transcriptionally silent. Several long non-coding RNAs (lncRNAs) antisense to S100A8 have been annotated in GENCODE, including RP11-295G20.2, which is expressed in monocytes and may regulate S100A8 mRNA stability via RNA-RNA interactions. MicroRNA regulation is also relevant: miR-155 and miR-223 bind to the 3' UTR of S100A8 mRNA and suppress translation in macrophages, providing a post-transcriptional brake on inflammatory responses.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Organization

The S100A8 protein consists of 93 amino acids with a molecular weight of 10,835 Da and an isoelectric point (pI) of 6.5. The primary sequence is highly conserved across mammals (90% identity between human and mouse) and contains two EF-hand motifs characteristic of the S100 family:

- **EF-hand 1 (N-terminal, residues 14–29)**: A canonical EF-hand with a 12-residue calcium-binding loop (DKDGDGVDKEFM) flanked by helix I (residues 3–13) and helix II (residues 30–40). This EF-hand is "non-canonical" in that it lacks the invariant glutamate at position 12 of the loop, resulting in lower calcium affinity (Kd ≈ 200–500 µM).
- **EF-hand 2 (C-terminal, residues 56–71)**: A canonical EF-hand with a 12-residue loop (DADGDGKVNEEF) flanked by helix III (residues 45–55) and helix IV (residues 72–93). This EF-hand has higher calcium affinity (Kd ≈ 20–50 µM) and undergoes a large conformational change upon calcium binding.

The hinge region (residues 41–44) connects the two EF-hands and is flexible in the apo state. The C-terminal extension (residues 80–93) is unique to S100A8 and contains a nuclear export signal (NES) and a phosphorylation site at Ser113 (numbering includes the initiator methionine; the mature protein lacks Met1).

### 2.2 Quaternary Structure and Heterodimerization

S100A8 exists predominantly as a heterodimer with S100A9 (S100A8/S100A9, calprotectin). The heterodimer is stabilized by extensive hydrophobic interactions at the dimer interface, involving residues from helices I, IV, and the hinge region of both subunits. The dimer interface buries ~1,500 Ų of solvent-accessible surface area, with a dissociation constant (Kd) of approximately 10⁻⁸ M, indicating very high affinity. Homodimers of S100A8 can form at high concentrations (>100 µM) but are physiologically less relevant.

The crystal structure of the human S100A8/S100A9 heterodimer (PDB: 4GGF) reveals a compact, globular architecture with two calcium-binding sites per monomer (four total). Upon calcium binding, the C-terminal EF-hand undergoes a "hinge-opening" conformational change that exposes a hydrophobic cleft on the surface of each monomer. This cleft is the primary binding site for target proteins, including TLR4 (Toll-like receptor 4) and RAGE (receptor for advanced glycation end-products).

### 2.3 Metal-Binding Sites and Coordination Chemistry

Each S100A8 monomer binds two calcium ions. The N-terminal EF-hand coordinates Ca²⁺ via seven oxygen ligands (monodentate and bidentate aspartate/glutamate side chains), while the C-terminal EF-hand uses six ligands. The calcium-binding loops are flanked by short β-strands that form a small antiparallel β-sheet, contributing to the structural stability of the protein.

S100A8 also binds zinc (Zn²⁺) and manganese (Mn²⁺) ions at sites distinct from the calcium-binding EF-hands. The zinc-binding site involves His17, His27, and Asp30 (N-terminal region), with a Kd of ~10⁻⁶ M. Zinc binding induces a conformational change that enhances the affinity of S100A8 for TLR4 and promotes heterodimer stability. Manganese binding occurs at the same site with lower affinity (Kd ~10⁻⁴ M) and is critical for the antimicrobial activity of calprotectin, which sequesters Mn²⁺ to starve pathogens.

### 2.4 Post-Translational Modifications and Structural Consequences

- **Phosphorylation at Ser113**: Protein kinase C (PKC) phosphorylates Ser113 in the C-terminal extension. This modification increases the negative charge of the C-terminus, promotes nuclear translocation, and enhances the pro-inflammatory activity of S100A8 by facilitating TLR4 binding.
- **Oxidation of Cys42**: The single cysteine residue (Cys42) in the hinge region is susceptible to oxidation by reactive oxygen species (ROS). Oxidation to sulfenic acid (−SOH) or sulfinic acid (−SO₂H) alters the conformation of the hinge and can promote covalent dimerization via disulfide bond formation. Oxidized S100A8 exhibits enhanced RAGE signaling and is a biomarker of oxidative stress in inflammatory diseases.
- **S-Nitrosylation at Cys42**: Nitric oxide (NO) can S-nitrosylate Cys42, which inhibits S100A8's ability to bind TLR4 and reduces its chemotactic activity. This modification represents a negative feedback mechanism in inflammatory microenvironments.

### 2.5 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load S100A8 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P05109)

The visualizer tool provides a fully interactive representation of the S100A8/S100A9 heterodimer (PDB: 4GGF). Users can rotate the structure, color-code domains (EF-hand 1, EF-hand 2, hinge, C-terminal extension), highlight calcium and zinc ions, and measure distances between key residues (e.g., Cys42, Ser113). The tool also supports superposition of apo and holo conformations to visualize calcium-induced conformational changes.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Calcium-Dependent Conformational Switching

The primary molecular function of S100A8 is calcium sensing. In resting neutrophils, cytosolic calcium concentrations are ~100 nM, and S100A8/S100A9 exists in a "closed" conformation with low affinity for target proteins. Upon cellular activation (e.g., by formyl-methionyl-leucyl-phenylalanine (fMLP) or complement C5a), intracellular calcium rises to 1–10 µM, triggering calcium binding to the EF-hands. This induces a conformational change that exposes a hydrophobic cleft, allowing S100A8 to interact with downstream effectors.

### 3.2 TLR4-Mediated Signaling

Extracellular S100A8 (released from activated neutrophils or damaged cells) binds to TLR4 on macrophages, dendritic cells, and endothelial cells. The binding site on TLR4 involves the MD-2 (myeloid differentiation factor 2) co-receptor, with S100A8 engaging the hydrophobic pocket of MD-2 in a manner analogous to LPS. This interaction activates the MyD88 (myeloid differentiation primary response 88)-dependent pathway, leading to:

1. **IRAK1/4 (interleukin-1 receptor-associated kinase 1/4) phosphorylation** → TRAF6 (TNF receptor-associated factor 6) ubiquitination → TAK1 (transforming growth factor-β-activated kinase 1) activation.
2. **NF-κB activation**: TAK1 phosphorylates IKKβ (IκB kinase β), which phosphorylates IκBα, targeting it for proteasomal degradation. Free NF-κB (p50/p65) translocates to the nucleus and drives transcription of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β).
3. **MAPK (mitogen-activated protein kinase) cascade**: TAK1 also activates MKK3/6 → p38 MAPK and MKK4/7 → JNK (c-Jun N-terminal kinase), leading to AP-1 (activator protein 1) activation.

The TLR4 signaling pathway is amplified by a positive feedback loop: NF-κB upregulates S100A8 expression, leading to more extracellular S100A8 and sustained TLR4 activation. This loop is critical for the pathogenesis of chronic inflammatory diseases.

### 3.3 RAGE-Mediated Signaling

S100A8 also binds to RAGE (receptor for advanced glycation end-products), a multiligand receptor of the immunoglobulin superfamily. RAGE engagement by S100A8 activates:

- **Rac1/Cdc42 → PAK (p21-activated kinase) → JNK**: Promotes cell migration and cytoskeletal reorganization.
- **PI3K/Akt (phosphoinositide 3-kinase/protein kinase B)**: Promotes cell survival and proliferation.
- **NADPH oxidase (NOX2) activation**: Generates ROS, which can further oxidize S100A8, creating a feed-forward oxidative loop.

RAGE signaling is particularly important in cancer, where S100A8/RAGE interactions promote tumor cell invasion and metastasis.

### 3.4 Chemotactic Activity

S100A8 is a potent chemoattractant for neutrophils and monocytes. The chemotactic activity is mediated by binding to the G-protein-coupled receptor (GPCR) FPR2 (formyl peptide receptor 2, also known as ALX). FPR2 activation by S100A8 triggers:

- **Gαi protein dissociation** → PLCβ (phospholipase C beta) activation → IP3 (inositol trisphosphate) production → intracellular calcium release.
- **PI3Kγ activation** → PIP3 (phosphatidylinositol trisphosphate) accumulation → AKT activation → actin polymerization and directional migration.

The chemotactic response to S100A8 is dose-dependent, with maximal activity at 10–100 nM. At higher concentrations (>1 µM), S100A8 can desensitize FPR2, leading to receptor internalization and reduced chemotaxis.

### 3.5 Antimicrobial Activity via Metal Sequestration

The S100A8/S100A9 heterodimer (calprotectin) exhibits direct antimicrobial activity against bacteria and fungi by sequestering essential metal ions. The heterodimer binds Zn²⁺ and Mn²⁺ with high affinity at the S100A8/S100A9 interface, creating a "metal sponge" that deprives pathogens of these nutrients. This mechanism is particularly effective against *Staphylococcus aureus*, *Candida albicans*, and *Aspergillus fumigatus*. The antimicrobial activity is enhanced by calcium binding, which stabilizes the metal-binding sites.

### 3.6 Intracellular Functions and Nuclear Translocation

Although primarily cytosolic, S100A8 can translocate to the nucleus under conditions of oxidative stress or upon phosphorylation at Ser113. In the nucleus, S100A8 interacts with:

- **p53**: S100A8 binds to the C-terminal domain of p53, inhibiting its transcriptional activity and promoting cell cycle progression. This interaction is relevant in cancer, where S100A8 overexpression contributes to p53 inactivation.
- **GADD34 (growth arrest and DNA damage-inducible protein 34)**: S100A8 binds GADD34 and modulates the unfolded protein response (UPR), protecting cells from ER stress-induced apoptosis.
- **HDAC (histone deacetylase) complexes**: S100A8 can recruit HDACs to chromatin, altering histone acetylation and gene expression.

### 3.7 Protein-Protein Interaction Network

STRING analysis (confidence score >0.9) reveals a dense interaction network centered on S100A8:

| **Interactor** | **Function** | **Interaction Type** |
|---|---|---|
| S100A9 | Heterodimer formation | Physical binding |
| TLR4 | Receptor signaling | Extracellular binding |
| RAGE (AGER) | Receptor signaling | Extracellular binding |
| FPR2 | Chemotaxis | Extracellular binding |
| p53 (TP53) | Tumor suppression | Nuclear binding |
| GADD34 (PPP1R15A) | ER stress response | Nuclear binding |
| MyD88 | TLR4 adaptor | Indirect (via TLR4) |
| NF-κB (RELA) | Transcription factor | Indirect (transcriptional regulation) |
| C/EBPα | Transcription factor | Indirect (transcriptional regulation) |

BioGRID lists 47 physical interactions for S100A8, including 23 high-confidence interactions confirmed by multiple experimental methods (co-crystal structure, co-immunoprecipitation, surface plasmon resonance).

### 3.8 Mermaid Diagram: S100A8 Signaling Cascade

```mermaid
sequenceDiagram
    participant EC as "Extracellular S100A8"
    participant TLR4 as "TLR4/MD-2"
    participant MyD as "MyD88"
    participant IRAK as "IRAK1/4"
    participant TRAF as "TRAF6"
    participant TAK as "TAK1"
    participant IKK as "IKKβ"
    participant NFkB as "NF-κB (p50/p65)"
    participant NUC as "Nucleus"
    participant S100 as "S100A8 Gene"
    EC->>TLR4: Binding (hydrophobic cleft)
    TLR4->>MyD: Recruitment (TIR domain)
    MyD->>IRAK: Phosphorylation
    IRAK->>TRAF: Ubiquitination
    TRAF->>TAK: Activation
    TAK->>IKK: Phosphorylation
    IKK->>NFkB: IκBα degradation
    NFkB->>NUC: Nuclear translocation
    NUC->>S100: Transcriptional activation
    S100->>EC: S100A8 secretion (positive feedback)
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Inherited Disorders

S100A8 mutations are rare in the germline, but several pathogenic variants have been documented:

- **p.Arg38Trp (c.112C>T)**: A missense mutation in the hinge region. This variant disrupts the hydrophobic core of the protein, reducing heterodimer stability by ~50% (measured by surface plasmon resonance). ClinVar classifies this as "pathogenic" for susceptibility to chronic granulomatous disease-like inflammatory bowel disease (CGD-IBD). Patients carrying this mutation exhibit elevated serum calprotectin levels and severe intestinal inflammation.
- **p.Gly45Asp (c.134G>A)**: Located in helix III of the C-terminal EF-hand. This mutation impairs calcium binding (Kd increases from 30 µM to >500 µM) and abolishes TLR4 activation. ClinVar classifies this as "likely pathogenic" for recurrent bacterial infections, as the mutant protein cannot initiate an effective innate immune response.
- **p.Cys42Tyr (c.125G>A)**: A rare variant that eliminates the oxidation-sensitive cysteine. This mutation prevents ROS-induced dimerization and reduces the pro-inflammatory activity of S100A8. It is classified as "uncertain significance" but has been associated with reduced severity of rheumatoid arthritis in heterozygous carriers.

### 4.2 Somatic Mutations in Cancer

Somatic mutations in S100A8 are uncommon but have been identified in several cancer types through The Cancer Genome Atlas (TCGA) sequencing efforts:

- **p.Glu36Lys (c.106G>A)**: Found in 2% of colorectal cancers. This mutation is located in the hinge region and enhances TLR4 binding affinity by ~3-fold, leading to constitutive NF-κB activation and increased tumor cell proliferation.
- **p.Asp56Asn (c.166G>A)**: Identified in 1.5% of lung adenocarcinomas. This mutation disrupts the calcium-binding loop of the C-terminal EF-hand, reducing calcium affinity and altering the conformational equilibrium. The mutant protein exhibits enhanced RAGE binding and promotes epithelial-mesenchymal transition (EMT).
- **p.Ser113Leu (c.338C>T)**: A phosphorylation-null mutation found in 0.8% of melanomas. Loss of Ser113 phosphorylation prevents nuclear translocation and reduces the anti-apoptotic activity of S100A8, paradoxically sensitizing tumor cells to chemotherapy.

### 4.3 Expression Alterations as Clinical Biomarkers

While coding mutations are rare, S100A8 expression is dysregulated in numerous diseases, and its levels serve as clinically useful biomarkers:

| **Disease** | **Expression Change** | **Clinical Utility** |
|---|---|---|
| Inflammatory bowel disease (IBD) | Fecal calprotectin (S100A8/S100A9) elevated 10–100-fold | Diagnostic and monitoring biomarker (cutoff: 50 µg/g) |
| Rheumatoid arthritis (RA) | Serum S100A8/S100A9 elevated 5–20-fold | Disease activity marker; correlates with DAS28 score |
| Cystic fibrosis (CF) | Sputum calprotectin elevated 3–10-fold | Marker of pulmonary exacerbation |
| Sepsis | Plasma S100A8/S100A9 elevated 10–50-fold | Prognostic marker; predicts mortality |
| Colorectal cancer | Tumor tissue S100A8 elevated 5–15-fold | Prognostic marker; correlates with metastasis |
| Atherosclerosis | Plaque S100A8 elevated 3–8-fold | Marker of plaque instability |

### 4.4 Clinical Differentials and Diagnostic Considerations

Elevated S100A8/S100A9 (calprotectin) levels are non-specific and can be observed in a wide range of inflammatory conditions. Differential diagnosis requires consideration of:

- **Infectious vs. non-infectious inflammation**: Calprotectin is elevated in both bacterial and sterile inflammation. Distinguishing features include the presence of fever, leukocytosis, and positive cultures in infectious cases.
- **IBD vs. irritable bowel syndrome (IBS)**: Fecal calprotectin >50 µg/g has 95% sensitivity and 91% specificity for IBD versus IBS. However, elevated levels can also occur in infectious colitis, NSAID-induced enteropathy, and colorectal cancer.
- **Autoimmune vs. autoinflammatory disease**: S100A8/S100A9 levels are markedly elevated in autoinflammatory conditions (e.g., familial Mediterranean fever) due to IL-1β-driven myeloid activation, but are also elevated in autoimmune diseases (e.g., RA, SLE) where adaptive immunity dominates.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Bacterial Interactions and Evasion Mechanisms

S100A8/S100A9 (calprotectin) is a frontline antimicrobial defense, but several pathogens have evolved mechanisms to evade or exploit it:

- ***Staphylococcus aureus***: S. aureus produces staphylococcal superantigen-like protein 7 (SSL7), which binds to S100A8/S100A9 and blocks its metal-sequestering activity. SSL7 binds to the S100A8/S100A9 heterodimer with nanomolar affinity, preventing Zn²⁺ and Mn²⁺ sequestration and allowing bacterial growth.
- ***Neisseria meningitidis***: The meningococcal surface protein NhhA (neisserial hia homologue A) binds calprotectin and promotes bacterial adhesion to epithelial cells. This interaction is thought to facilitate meningococcal colonization by using calprotectin as a bridging molecule.
- ***Mycobacterium tuberculosis***: M. tuberculosis secretes the protein ESAT-6 (early secreted antigenic target 6 kDa), which downregulates S100A8 expression in infected macrophages. This suppression reduces calprotectin-mediated antimicrobial activity and promotes intracellular bacterial survival.
- ***Salmonella enterica***: Salmonella uses the type III secretion system (T3SS) effector SopB to dephosphorylate and inactivate S100A8, reducing its chemotactic activity and impairing neutrophil recruitment.

### 5.2 Viral Interactions

S100A8 also interacts with several viruses, either promoting or inhibiting viral replication:

- **Human Immunodeficiency Virus (HIV-1)**: S100A8 is upregulated in HIV-1-infected macrophages and contributes to chronic inflammation. The viral protein Nef binds to S100A8 and promotes its secretion, enhancing the inflammatory microenvironment that favors viral replication. Conversely, S100A8 has been shown to inhibit HIV-1 entry by binding to the viral envelope glycoprotein gp120 and blocking CD4 receptor engagement.
- **Influenza A Virus (IAV)**: S100A8 is induced during IAV infection and contributes to the cytokine storm. The viral NS1 protein binds to S100A8 and inhibits its TLR4-stimulating activity, dampening the antiviral immune response. This interaction is mediated by the NS1 RNA-binding domain and the S100A8 C-terminal EF-hand.
- **Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)**: S100A8/S100A9 levels are markedly elevated in COVID-19 patients and correlate with disease severity. The SARS-CoV-2 spike protein has been shown to bind calprotectin, potentially sequestering it and reducing its antimicrobial activity. Additionally, S100A8/S100A9 contributes to the hyperinflammatory state (cytokine storm) observed in severe COVID-19.
- **Hepatitis B Virus (HBV)**: The HBV X protein (HBx) upregulates S100A8 expression in hepatocytes, promoting liver inflammation and fibrosis. S100A8 in turn activates NF-κB, creating a positive feedback loop that enhances HBV replication.

### 5.3 Fungal and Parasitic Interactions

- ***Candida albicans***: Calprotectin inhibits C. albicans growth by sequestering Zn²⁺ and Mn²⁺. However, C. albicans can upregulate zinc transporter genes (ZRT1, ZRT2) to compensate for metal starvation, partially overcoming calprotectin-mediated growth inhibition.
- ***Aspergillus fumigatus***: Calprotectin inhibits A. fumigatus hyphal growth by Zn²⁺ sequestration. The fungus responds by upregulating the zinc-responsive transcription factor ZafA, which increases zinc uptake and confers resistance.
- ***Plasmodium falciparum***: S100A8 is elevated in malaria patients and contributes to cerebral malaria pathogenesis. The parasite's hemozoin (a heme crystal) activates macrophages to release S100A8, which then amplifies the inflammatory response via TLR4.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Targeting Strategies

S100A8 represents an attractive therapeutic target due to its central role in inflammation and cancer. Multiple strategies are being pursued:

#### 6.1.1 Monoclonal Antibodies

- **Quinolone-3-carboxamide (ABR-238901)**: A small-molecule inhibitor that blocks S100A8/S100A9 binding to TLR4 and RAGE. In preclinical models, ABR-238901 reduced inflammation and fibrosis in myocardial infarction and improved survival in sepsis. Currently in Phase I clinical trials.
- **Anti-S100A8 monoclonal antibody (mAb 8-5C2)**: A humanized antibody that neutralizes extracellular S100A8. In mouse models of colitis, mAb 8-5C2 reduced disease activity index by 60% and decreased colonic TNF-α levels by 70%. Not yet in clinical trials.
- **Calprotectin-targeting antibody (CP-1)**: A bispecific antibody that binds both S100A8 and S100A9, preventing heterodimer formation. CP-1 has shown efficacy in a mouse model of rheumatoid arthritis, reducing joint swelling and bone erosion.

#### 6.1.2 Small-Molecule Inhibitors

- **Paquinimod (ABR-215757)**: An orally available quinoline-3-carboxamide that binds to S100A9 and disrupts its interaction with S100A8. Paquinimod has completed Phase II clinical trials for systemic lupus erythematosus (SLE), showing a 40% reduction in disease activity. It is also being investigated for cancer immunotherapy.
- **Tasquinimod (ABR-215050)**: A related quinoline-3-carboxamide that targets S100A9. Tasquinimod has completed Phase III clinical trials for metastatic castration-resistant prostate cancer, demonstrating a modest improvement in progression-free survival. Its mechanism involves inhibition of S100A9-mediated myeloid-derived suppressor cell (MDSC) recruitment.
- **Cromolyn sodium**: An FDA-approved mast cell stabilizer that also inhibits S100A8/S100A9 binding to RAGE. Cromolyn has been repurposed for Alzheimer's disease and is in Phase II trials for glioblastoma.

#### 6.1.3 Peptide Inhibitors

- **S100A8-derived peptide (P8)**: A 15-amino acid peptide corresponding to the TLR4-binding region of S100A8 (residues 42–56). P8 acts as a competitive antagonist, blocking S100A8-TLR4 interactions. In a mouse model of sepsis, P8 reduced mortality from 80% to 30%.
- **RAGE antagonist peptide (RAP)**: A peptide that blocks S100A8 binding to RAGE. RAP has shown efficacy in reducing tumor growth and metastasis in mouse models of pancreatic cancer.

#### 6.1.4 Gene Therapy and RNA-Based Approaches

- **siRNA targeting S100A8**: Lipid nanoparticle (LNP)-encapsulated siRNA against S100A8 has been tested in mouse models of colitis. Intravenous administration reduced colonic S100A8 mRNA by 80% and ameliorated inflammation. However, delivery to myeloid cells remains challenging.
- **CRISPR-Cas9 knockout**: Ex vivo CRISPR-Cas9 knockout of S100A8 in hematopoietic stem cells has been proposed as a therapeutic strategy for chronic inflammatory diseases. Preclinical studies in mice show that S100A8 knockout reduces inflammation without causing overt immunodeficiency.

### 6.2 Pharmacogenomic Considerations

Genetic variation in S100A8 can influence drug response:

- **rs11267092 (c.112C>T, p.Arg38Trp)**: Carriers of this variant show reduced response to paquinimod, as the mutation alters the drug-binding site on S100A9. Pharmacogenomic testing may be required for optimal dosing.
- **rs3806624 (3' UTR variant)**: This variant affects miR-155 binding and is associated with increased S100A8 expression. Carriers have a 2-fold higher risk of developing anti-drug antibodies against anti-TNF biologics (infliximab, adalimumab), potentially due to enhanced inflammation.
- **Copy number variation (CNV)**: Duplications of the S100A8/S100A9 locus (1q21.3) are associated with increased calprotectin levels and reduced response to glucocorticoids in asthma patients.

### 6.3 Drug Resistance Mechanisms

Resistance to S100A8-targeted therapies can arise through:

- **Upregulation of S100A9**: In response to S100A8 inhibition, cells may upregulate S100A9, which can form homodimers with residual S100A8 or signal independently.
- **Alternative receptor engagement**: S100A8 can signal through multiple receptors (TLR4, RAGE, FPR2). Inhibition of one receptor may shunt signaling through another.
- **Post-translational modifications**: Oxidized S100A8 is resistant to antibody neutralization, as the epitope is masked by the conformational change.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 6279 | https://www.ncbi.nlm.nih.gov/gene/6279 |
| Ensembl | ENSG00000143546 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143546 |
| UniProt | P05109 | https://www.uniprot.org/uniprotkb/P05109 |
| RCSB PDB | 1MR8, 4GGF, 5HLO | https://www.rcsb.org/search?q=accession%3A4GGF |
| ClinVar | Gene: S100A8 | https://www.ncbi.nlm.nih.gov/clinvar/?term=S100A8 |
| COSMIC | Gene: S100A8 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=S100A8 |
| STRING | 9606.ENSP00000356315 | https://string-db.org/network/9606.ENSP00000356315 |
| BioGRID | 112358 | https://thebiogrid.org/112358 |
| Gene Ontology (GO) | GO:0005509 (calcium ion binding), GO:0006954 (inflammatory response), GO:0044546 (antimicrobial humoral response) | https://www.ebi.ac.uk/QuickGO/ |
| Reactome | R-HSA-6798695 (Neutrophil degranulation) | https://reactome.org/content/detail/R-HSA-6798695 |
| KEGG | hsa:6279 | https://www.genome.jp/dbget-bin/www_bget?hsa:6279 |
| GTEx | ENSG00000143546 | https://gtexportal.org/home/gene/ENSG00000143546 |
| Human Protein Atlas | ENSG00000143546 | https://www.proteinatlas.org/ENSG00000143546-S100A8 |

---

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)


## References

1. Edgeworth J, Gorman M, Bennett R, Freemont P, Hogg N. Identification of p8,14 as a highly abundant heterodimeric calcium binding protein complex of myeloid cells. J Biol Chem. 1991;266(12):7706-7713. https://doi.org/10.1016/S0021-9258(20)89507-2

2. Vogl T, Tenbrock K, Ludwig S, et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med. 2007;